Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma

Toxicology and Applied Pharmacology

Volumn 232, Issue 2, 2008, Pages 203-209

  Chung, Chi Jung ^a   Huang, Chi Jung ^a   Pu, Yeong Shiau ^b   Su, Chien Tien ^c   Huang, Yung Kai ^a   Chen, Ying Ting ^a   Hsueh, Yu Mei ^d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

8 hydroxydeoxyguanine; CCND1; Cell cycle; p21; p53; Polymorphism; Urinary arsenic profile; Urothelial carcinoma

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADENINE; ARSENIC; CACODYLIC ACID; GUANINE; METHANEARSONIC ACID;

ADULT; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER RISK; CASE CONTROL STUDY; CCND1 GENE; CELL CYCLE; CELL CYCLE REGULATION; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYDRIDE GENERATOR ATOMIC ABSORPTION SPECTROMETRY; MAJOR CLINICAL STUDY; MALE; P21 GENE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; TUMOR SUPPRESSOR GENE;

ARSENIC; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DEOXYGUANOSINE; FEMALE; GENES, CDC; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; VARIATION (GENETICS);

EID: 52049091455     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.06.011     Document Type: Article

References (69)

1. Ara S., Lee P.S., Hansen M.F., and Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic. Acids. Res. 18 (1990) 4961
2. Bahl R., Arora S., Nath N., Mathur M., Shukla N.K., and Ralhan R. Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer. Oncogene 19 (2000) 323-328
3. Bates M.N., Smith A.H., and Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. Am. J. Epidemiol. 135 (1992) 462-476
4. Betticher D.C., Thatcher N., Altermatt H.J., Hoban P., Ryder W.D., and Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11 (1995) 1005-1011
5. Cai K., and Dynlacht B.D. Activity and nature of p21(WAF1) complexes during the cell cycle. Proc. Natl. Acad. Sci. U.S.A 95 (1998) 12254-12259
6. Ceschi M., Sun C.L., Van Den B.D., Koh W.P., Yu M.C., and Probst-Hensch N. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 26 (2005) 1457-1464
7. Chanda S., Dasgupta U.B., Guhamazumder D., Gupta M., Chaudhuri U., Lahiri S., Das S., Ghosh N., and Chatterjee D. DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. Toxicol. Sci. 89 (2006) 431-437
8. Chedid M., Michieli P., Lengel C., Huppi K., and Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 9 (1994) 3021-3024
9. Chen W.C., Wu H.C., Hsu C.D., Chen H.Y., and Tsai F.J. p21 gene codon 31 polymorphism is associated with bladder cancer. Urol. Oncol. 7 (2002) 63-66
10. Chen Y.C., Amarasiriwardena C.J., Hsueh Y.M., and Christiani D.C. Stability of arsenic species and insoluble arsenic in human urine. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 1427-1433
11. Chen Y.C., Xu L., Guo Y.L., Su H.J., Smith T.J., Ryan L.M., Lee M.S., and Christiani D.C. Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: a preliminary study. Biomarkers 9 (2004) 386-394
12. Chung C.J., Huang C.J., Pu Y.S., Su C.T., Huang Y.K., Chen Y.T., and Hsueh Y.M. Urinary 8-hydroxydeoxyguanosine and urothelial carcinoma risk in low arsenic exposure area. Toxicol. Appl. Pharmacol. 226 (2008) 14-21
13. Cohen S.M., Ohnishi T., Arnold L.L., and Le X.C. Arsenic-induced bladder cancer in an animal model. Toxicol. Appl. Pharmacol. 222 (2007) 258-263
14. Cortessis V.K., Siegmund K., Xue S., Ross R.K., and Yu M.C. A case-control study of cyclin D1 CCND1 870A->G polymorphism and bladder cancer. Carcinogenesis 24 (2003) 1645-1650
15. De C.S., Mahata J., Das J.K., Mukherjee A., Ghosh P., Sau T.J., Mondal L., Basu S., Giri A.K., and Roychoudhury S. Association of specific p53 polymorphisms with keratosis in individuals exposed to arsenic through drinking water in West Bengal, India. Mutat. Res. 601 (2006) 102-112
16. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
17. Furihata M., Takeuchi T., Matsumoto M., Kurabayashi A., Ohtsuki Y., Terao N., Kuwahara M., and Shuin T. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin. Cancer Res. 8 (2002) 1192-1195
18. Gonsebatt M.E., Vega L., Herrera L.A., Montero R., Rojas E., Cebrian M.E., and Ostrosky-Wegman P. Inorganic arsenic effects on human lymphocyte stimulation and proliferation. Mutat. Res. 283 (1992) 91-95
19. Gumerlock P.H., Chi S.G., Shi X.B., Voeller H.J., Jacobson J.W., Gelmann E.P., and Vere White R.W. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. JNCI Journal of the National Cancer Institute 89 (1997) 66-71
20. Hall M.C., Li Y., Pong R.C., Ely B., Sagalowsky A.I., and Hsieh J.T. The growth inhibitory effect of p21 adenovirus on human bladder cancer cells. J. Urol. 163 (2000) 1033-1038
21. Hamadeh H.K., Vargas M., Lee E., and Menzel D.B. Arsenic disrupts cellular levels of p53 and mdm2: a potential mechanism of carcinogenesis. Biochem. Biophys. Res. Commun. 263 (1999) 446-449
22. Hartwig A., Asmuss M., Ehleben I., Herzer U., Kostelac D., Pelzer A., Schwerdtle T., and Burkle A. Interference by toxic metal ions with DNA repair processes and cell cycle control: molecular mechanisms. Environ. Health. Perspect. 110 Suppl 5 (2002) 797-799
23. Hartwig A., Blessing H., Schwerdtle T., and Walter I. Modulation of DNA repair processes by arsenic and selenium compounds. Toxicology 193 (2003) 161-169
24. Hernandez-Zavala A., Cordova E., Del Razo L.M., Cebrian M.E., and Garrido E. Effects of arsenite on cell cycle progression in a human bladder cancer cell line. Toxicology 207 (2005) 49-57
25. Hsieh Y.Y., Tsai F.J., Chang C.C., Chen W.C., Tsai C.H., Tsai H.D., and Lin C.C. p21 gene codon 31 arginine/serine polymorphism: non-association with endometriosis. J. Clin. Lab. Anal. 15 (2001) 184-187
26. Hsueh Y.M., Huang Y.L., Huang C.C., Wu W.L., Chen H.M., Yang M.H., Lue L.C., and Chen C.J. Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J. Toxicol. Environ. Health 54 (1998) 431-444
27. Hsueh Y.M., Hsu M.K., Chiou H.Y., Yang M.H., Huang C.C., and Chen C.J. Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake. Toxicol. Lett. 133 (2002) 83-91
28. Huang S.P., Wu W.J., Chang W.S., Wu M.T., Chen Y.Y., Chen Y.J., Yu C.C., Wu T.T., Lee Y.H., Huang J.K., and Huang C.H. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 2217-2224
29. Huppi K., Siwarski D., Dosik J., Michieli P., Chedid M., Reed S., Mock B., Givol D., and Mushinski J.F. Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1). Oncogene 9 (1994) 3017-3020
30. Izzo J.G., Papadimitrakopoulou V.A., Liu D.D., den Hollander P.L., Babenko I.M., Keck J., El-Naggar A.K., Shin D.M., Lee J.J., Hong W.K., and Hittelman W.N. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. JNCI Journal of the National Cancer Institute 95 (2003) 198-205
31. Jain M., Kumar S., Lal P., Tiwari A., Ghoshal U.C., and Mittal B. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect. Prev. 31 (2007) 225-232
32. Kelsey K.T., Hirao T., Hirao S., vi-Ashok T., Nelson H.H., Andrew A., Colt J., Baris D., Morris J.S., Schned A., and Karagas M. TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. Int. J. Cancer 117 (2005) 370-375
33. Keshava C., Frye B.L., Wolff M.S., McCanlies E.C., and Weston A. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 127-130
34. Kitchin K.T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 172 (2001) 249-261
35. Ko L.J., and Prives C. p53: puzzle and paradigm. Genes Dev. 10 (1996) 1054-1072
36. Koopmann J., Maintz D., Schild S., Schramm J., Louis D.N., Wiestler O.D., and von D.A. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Br. J. Cancer 72 (1995) 1230-1233
37. Kuroda Y., Tsukino H., Nakao H., Imai H., and Katoh T. p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett. 189 (2003) 77-83
38. Le M.L., Seifried A., Lum-Jones A., Donlon T., and Wilkens L.R. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA: The Journal of the American Medical Association 290 (2003) 2843-2848
39. Lee J.M., Shun C.T., Wu M.T., Chen Y.Y., Yang S.Y., Hung H.I., Chen J.S., Hsu H.H., Huang P.M., Kuo S.W., and Lee Y.C. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat. Res. 594 (2006) 181-188
40. Lewis R.C., Bostick R.M., Xie D., Deng Z., Wargovich M.J., Fina M.F., Roufail W.M., and Geisinger K.R. Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. Cancer Res. 63 (2003) 8549-8553
41. Li Y.J., Laurent-Puig P., Salmon R.J., Thomas G., and Hamelin R. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 10 (1995) 599-601
42. Maddika S., Ande S.R., Panigrahi S., Paranjothy T., Weglarczyk K., Zuse A., Eshraghi M., Manda K.D., Wiechec E., and Los M. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist. Updat. 10 (2007) 13-29
43. Makri D., Schulz W.A., Grimm M., Clasen S., Bojar H., and Schmitz-Drager B.J. WAF1/p21 regulates proliferation, but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines. Int. J. Oncol. 12 (1998) 621-628
44. Moore L.E., Smith A.H., Eng C., DeVries S., Kalman D., Bhargava V., Chew K., Ferreccio C., Rey O.A., Hopenhayn C., Biggs M.L., Bates M.N., and Waldman F.M. P53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis 24 (2003) 1785-1791
45. Mousses S., Ozcelik H., Lee P.D., Malkin D., Bull S.B., and Andrulis I.L. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum. Mol. Genet. 4 (1995) 1089-1092
46. Ozdemir E., Kakehi Y., and Yoshida O. p21(WAF-1/CIP-1), a downstream regulator of functional p53 loss, in transitional cell carcinoma of urothelium. Eur. Urol. 38 (2000) 230-234
47. Papadakis E.N., Dokianakis D.N., and Spandidos D.A. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol. Cell Biol. Res. Commun. 3 (2000) 389-392
48. Pilger A., Ivancsits S., Germadnik D., and Riger H.W. Urinary excretion of 8-hydroxy-2'-deoxyguanosine measured by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B 778 (2002) 393-401
49. Pu Y.S., Yang S.M., Huang Y.K., Chung C.J., Huang S.K., Chiu A.W., Yang M.H., Chen C.J., and Hsueh Y.M. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol. Appl. Pharmacol. 218 (2007) 99-106
50. Ralhan R., Agarwal S., Mathur M., Wasylyk B., and Srivastava A. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer. Clin. Cancer Res. 6 (2000) 2440-2447
51. Ressiniotis T., Griffiths P.G., Keers S.M., Chinnery P.F., and Birch M. A polymorphism at codon 31 of gene p21 is not associated with primary open angle glaucoma in Caucasians. BMC. Ophthalmol. 5 (2005) 5
52. Roh J., Kim M., Kim J., Park N., Song Y., Kang S., and Lee H. Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett. 165 (2001) 59-62
53. Settheetham-Ishida W., Singto Y., Yuenyao P., Tassaneeyakul W., Kanjanavirojkul N., and Ishida T. Contribution of epigenetic risk factors but not p53 codon 72 polymorphism to the development of cervical cancer in Northeastern Thailand. Cancer Lett. 210 (2004) 205-211
54. Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., Beckman G., and Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17 (1996) 1313-1316
55. Soulitzis N., Sourvinos G., Dokianakis D.N., and Spandidos D.A. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 179 (2002) 175-183
56. Su L., Liu G., Zhou W., Xu L.L., Miller D.P., Park S., Lynch T.J., Wain J.C., and Christiani D.C. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 174-175
57. Sun Y., Hildesheim A., Li H., Li Y., Chen J.Y., Cheng Y.J., Hayes R.B., Rothman N., Bi W.F., and Cao Y. No point mutation but a codon 31ser->arg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol. Biomarkers Prev. 4 (1995) 261-267
58. Sun Y., Keshava C., Sharp D.S., Weston A., and McCanlies E.C. DNA sequence variants of p53: cancer and aging. Am. J. Hum. Genet. 65 (1999) 1779-1782
59. Tapio S., and Grosche B. Arsenic in the aetiology of cancer. Mutat. Res. 612 (2006) 215-246
60. Toruner G.A., Ucar A., Tez M., Cetinkaya M., Ozen H., and Ozcelik T. P53 codon 72 polymorphism in bladder cancer-no evidence of association with increased risk or invasiveness. Urol. Res. 29 (2001) 393-395
61. Tsai M.H., Chen W.C., and Tsai F.J. Correlation of p21 gene codon 31 polymorphism and TNF-alpha gene polymorphism with nasopharyngeal carcinoma. J. Clin. Lab. Anal. 16 (2002) 146-150
62. Wong Y.K., Lin S.C., Chang C.S., Tseng Y.H., Liu C.J., Lin H.C., and Chang K.W. Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J. Oral Pathol. Med. 32 (2003) 265-270
63. Wu M.T., Wu D.C., Hsu H.K., Kao E.L., Yang C.H., and Lee J.M. Association between p21 codon 31 polymorphism and esophageal cancer risk in a Taiwanese population. Cancer Lett. 201 (2003) 175-180
64. Xie H.L., Su Q., He X.S., Liang X.Q., Zhou J.G., Song Y., and Li Y.Q. Expression of p21(WAF1) and p53 and polymorphism of p21(WAF1) gene in gastric carcinoma. World J. Gastroenterol. 10 (2004) 1125-1131
65. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704
66. Yoshida T., Yamauchi H., and Fan S.G. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol. Appl. Pharmacol. 198 (2004) 243-252
67. Yu C., Lu W., Tan W., Xing D., Liang G., Miao X., and Lin D. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 176
68. Zhang X., Miao X., Guo Y., Tan W., Zhou Y., Sun T., Wang Y., and Lin D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat. 27 (2006) 110-117
69. Zlotta A.R., Noel J.C., Fayt I., Drowart A., Van Vooren J.P., Huygen K., Simon J., and Schulman C.C. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J. Urol. 161 (1999) 792-798